RedHill announces launch of Talicia in UAE to treat bacterial infection

RedHill Biopharma, a US-based specialty biopharmaceutical company, has announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE), making it available by prescription to treat adults with Helicobacter pylori (H. pylori) infection.

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori. 

H. pylori is a bacterial infection that affects approximately 35% of the U.S. population, with an estimated two million patients treated annually. Worldwide, more than 50% of the population has H. pylori infection, which is classified by the WHO as a Group 1 carcinogen.

Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the US FDA for the treatment of H. pylori infection in adults.